Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders

Int J Mol Sci. 2022 Sep 16;23(18):10831. doi: 10.3390/ijms231810831.

Abstract

Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn alone. Regression analyses showed an association of higher Ng concentrations with MMSE < 24, pathological Aβ 42/40 ratios, pTau, tTau and the ApoEε4 genotype. Aβ 42/Ng was associated with MMSE < 24, an AD-related FDG-PET pattern, the ApoEε4 genotype, pathological Aβ 42 levels and Aβ 42/40 ratios, pTau, and tTau. Moreover, APO-Eε4 carriers showed higher Ng concentrations than non-carriers. Our results support the idea that the Aβ 42/Ng ratio is a reliable index of synaptic dysfunction/degeneration able to discriminate AD from other neurological conditions.

Keywords: Alzheimer’s disease; biomarkers; neurogranin; α-synuclein.

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / genetics
  • Amyloid beta-Peptides
  • Biomarkers
  • Cognitive Dysfunction*
  • Fluorodeoxyglucose F18
  • Humans
  • Neurodegenerative Diseases*
  • Neurogranin / genetics
  • alpha-Synuclein / genetics
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • alpha-Synuclein
  • tau Proteins
  • Fluorodeoxyglucose F18
  • Neurogranin

Grants and funding

This research received no external funding.